

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

Company name Orasis Pharmaceuticals * Website www.orasis-pharma.com *

CEO name Elad Kedar

Select a CATEGORY: Biotech/Pharma *

Select up to two SESSIONS per abstract from the list below *

Ophthalmology from R&D to Commercialization

- **Executive Summary / Investment Rational**

Orasis Pharmaceuticals is developing CSF-1, a corrective eye drop for the treatment of presbyopia. Orasis is led by a collaborative team of industry executives and eye care specialists with a broad range of experiences in research, development, and commercialization of pharmaceutical drugs, as well as finance and business development. Orasis is funded by a diverse group of sophisticated and experienced life science and healthcare investors including the ophthalmology focused venture capital fund Visionary Ventures, Sequoia Capital, SBI (Japan) Innovation Fund, Bluestem Capital, LifeSci Venture Partners, Maverick Ventures Israel, and other private investors. Orasis has offices in the U.S. and Israel.
- **Core Technology**

CSF-1 is a novel corrective eye drop candidate being investigated for the treatment of presbyopia. CSF-1 is a proprietary, preservative-free formulation of low-dose pilocarpine and multi-faceted vehicle designed to achieve an optimal balance between efficacy, safety and comfort. CSF-1 improves near visual acuity by pupil modulation, resulting in a “pinhole effect” and an increase in the depth of field, thus increasing the ability to focus on near objects.
- **Product Profile/Pipeline**

Orasis submitted an NDA for CSF-1 and has received a PDUFA goal date of October 22, 2023. Orasis plans to launch CSF-1 in the US market in Q1 2024. Additional global markets are under consideration for filing and launch once CSF-1 is approved in the US.
- **Business Strategy**

Orasis is focused on the US launch plan, building out a commercial organization to launch CSF-1. CSF-1 will be the second to market in this novel, new category with a strong educational focus on the eye care professional (optometrists/ophthalmologists) and presbyopia patient to engage and delight.
- **What's Next?**

Orasis is awaiting approval from the FDA (October 2023) with a launch in Q1 2024. We are now focused on Organizational plans to build out the commercial launch team.

